ArticleMolecular and cellular biochemistry2026
ZNF384-regulated SLC31A1 expression promotes tumor proliferation and invasion in breast cancer.
Article in Molecular and cellular biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundSLC31A1, a copper transporter, has been implicated in copper metabolism processes. This study aims to explore the function and potential regulatory mechanisms of SLC31A1 in breast cancer.
methodsThe TCGA database was utilized to analyze SLC31A1 expression across various cancer types. SLC31A1 expression in breast cancer tissues was validated in an independent cohort of 80 paired breast cancer and adjacent normal tissues. SLC31A1 expression was manipulated in MCF-7 and BT-549 breast cancer cells using shRNA and overexpression vectors. Cell proliferation, colony formation, and invasion assays were performed to assess the functional consequences of SLC31A1 manipulation. ZNF384, a potential transcription factor for SLC31A1, was identified through bioinformatics analysis, and its binding to the SLC31A1 promoter was confirmed using dual-luciferase reporter assays and chromatin immunoprecipitation (ChIP).
resultsSLC31A1 expression was significantly elevated in breast cancer tissues, and high expression was associated with poor prognosis. SLC31A1 promoted cell viability, colony formation, and invasion. ZNF384 was identified as a transcription factor that regulates SLC31A1 expression, and its overexpression enhanced SLC31A1 expression, while knockdown of ZNF384 inhibited breast cancer cell proliferation and invasion. ChIP assays confirmed a direct interaction between ZNF384 and the SLC31A1 promoter.
conclusionSLC31A1 plays a crucial role in the proliferation and invasion of breast cancer cells, and its expression is regulated by ZNF384. These findings highlight SLC31A1 as a potential therapeutic target and suggest that modulation of copper metabolism may offer novel strategies for breast cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.